Downs Christopher 4
4 · CNS Pharmaceuticals, Inc. · Filed Feb 6, 2024
Insider Transaction Report
Form 4
Downs Christopher
Chief Financial Officer
Transactions
- Purchase
Common stock
2024-02-01$0.30/sh+66,666$20,000→ 103,438 total - Award
Series B Warrant to purchase common stock
2024-02-01+66,666→ 161,572 totalExercise: $0.30From: 2024-02-01Exp: 2025-10-01→ Common Stock (66,666 underlying) - Award
Series A Warrant to purchase common stock
2024-02-01+66,666→ 94,906 totalExercise: $0.30From: 2024-02-01Exp: 2029-02-01→ Common Stock (66,666 underlying)
Footnotes (1)
- [F1]The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.